Fig. 5: Overexpression of SPPL3 results in loss of CD19 surface expression.

a Sequential flow cytometric evaluation of FMC63-APC binding on SPPL3^KO + Nalm6 after overexpression of SPPL3. b Western blot of fractionated cellular lysates from WT, SPPL3^KO or SPPL3^KO with overexpression of SPPL3 (SPPL3^KO+) Nalm6 cells probed for CD19 performed 20 days after engineering. Representative of n = 2 individual experiments. c Survival of WT, SPPL3^KO, or SPPL3^KO + Nalm6 over time when established on 20 days after re-introduction of SPPL3 (E:T 0.25:1). Representative data from n = 2 experiments with independent T cell donors. Error bars reflect mean ± standard error of the mean (s.e.m.). ****P < 0.0001 by two-way ANOVA with Bonferroni correction for multiple comparisons. Statistical annotations reflect differences between WT and SPPL3^KO (upper) or WT and SPPL3^KO + Nalm6 (lower). Source Data are provided as a Source Data file.